Temporal trends in the incidence of malignancy in heart failure: a nationwide Danish study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Aims
Cancer and heart failure (HF) share risk factors, pathophysiological mechanisms, and possibly genetics. Improved HF survival may increase the risk of cancer due to a competing risk. Whether the incidence of cancer has increased over time in patients with HF as survival has improved is unclear. Therefore, temporal trends of new onset cancer in HF patients between 1997 and 2016 were investigated.

Methods and results
Using Danish nationwide registers, 103 711 individuals alive, free of cancer, and aged 30–80 years 1 year after HF diagnosis (index date) were included between 1 January 1997 and 31 December 2016. A five-year incidence rate of cancer for each year after index date was calculated. The median age and proportion of women at the index date decreased with advancing calendar time [1997–2001: 70.3 interquartile range (Q1–Q3 62.5–75.7), 60.9% men; 2012–16: 67.6 (59.2–73.8), 67.5% men]. The five-year incidence rate of cancer was 20.9 and 20.2 per 1,000 person-years in 1997 and 2016, respectively. In a multivariable Cox regression model, the hazard rates between index years 1997 (reference) and 2016 were not significantly different [hazard ratio 1.09 (0.97–1.23)]. The five-year absolute risk of cancer did not change with advancing calendar year, going from 9.0% (1997–2001) to 9.0% (2012–16). Five-year cumulative incidence of survival for HF patients increased with advancing calendar year, going from 55.9% (1997–2001) to 74.3% (2012–2016).

Conclusion
Although cancer rates during 1997–2016 have remained stable within 1–6 years after the HF diagnosis, long-term survival following a HF diagnosis has increased significantly.
OriginalsprogEngelsk
TidsskriftEuropean Heart Journal
Vol/bind44
Udgave nummer13
Sider (fra-til)1124-1132
Antal sider9
ISSN0195-668X
DOI
StatusUdgivet - 2023

Bibliografisk note

Funding Information:
Conflict of interest: C.H.G. reports personal fees from lectures honorarium from Astra Zeneca unrelated to the work in question; C.T.-P. reports grants from Bayer and Novo Nordisk unrelated to the work in question; J.V.M. reports grants from Abbott, Alkem Metabolics, Eris Lifesciences, Hikma, Lupin, Sun Pharmaceuticals, Medscape/Heart.Org, ProAdWise Communications, Radcliffe Cardiology, Servier, the Corpus unrelated to the work in question; N.N.L. reports grants from Roche Diagnostics, Boehringer Ingelheim, AstraZeneca, NIHR and British Heart Foundation. Further, reports lecturer fees from Roche, Pfizer, and Novartis and consulting fees from AstraZeneca. All unrelated to the work in question; L.K. reports personal fees from speakers honorarium from Novo Nordisk, Novartis, AstraZeneca and Boehringer Ingelheim outside the submitted work; M.S. reports personal fees from lectures honorarium from Novo Nordisk, Novartis, AstraZeneca, and Boehringer Ingelheim outside the submitted work.

Publisher Copyright:
© 2023 The Author(s). Published by Oxford University Press on behalf of the European Society of Cardiology. All rights reserved.

ID: 366766086